ClinicaliQ Trial Snapshot
- Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) — Active Not Recruiting • Phase III • Cardiology / Cardiovascular • NCT06274801.
- Long-term safety and effectiveness study of inhaled seralutinib for pulmonary hypertension patients who previously completed earlier trials.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study Conditions: Pulmonary Arterial Hypertension Interventions: Seralutinib, Gereic Dry Powder Inhaler Lead Sponsor: GB002, Inc. Planned Enrollment: 316 participants